Tillkännagivande • Sep 10
Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation The US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024. Tillkännagivande • Aug 03
Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals Corporation DMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash. Tillkännagivande • Jun 15
First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals Corporation The US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively. Tillkännagivande • May 09
Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation The US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer. Tillkännagivande • Mar 22
Nasdaq to Delist Common Stock of DMK Pharmaceuticals Nasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time. Tillkännagivande • Feb 08
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index Tillkännagivande • Feb 07
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index DMK Pharmaceuticals Corporation has been dropped from Nasdaq Composite Index. Tillkännagivande • Jan 06
DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024 DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024, at 09:00 Pacific Standard Time. Tillkännagivande • Nov 29
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders. Tillkännagivande • Nov 22
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index Adamis Pharmaceuticals Corporation has been dropped from NASDAQ Composite Index. Tillkännagivande • Oct 21
DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock Market On October 18, 2023, DMK Pharmaceuticals Corporation received a superseding notice from the Staff, indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company's non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company's request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing. Tillkännagivande • Oct 18
DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market As previously disclosed, on April 12, 2023, DMK Pharmaceuticals Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the market value of the Company’s common stock closed below the minimum $35 million threshold required by Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until October 9, 2023, to regain compliance with the Rule. On October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with the Rule prior to the expiration of any extension that may be granted to the Company following the hearing. Tillkännagivande • Oct 11
DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirements On October 4, 2023, DMK Pharmaceuticals Corporation received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock. The Notice indicated that the Nasdaq Listing Rules provide the Company a compliance period of 180 calendar days from the date of the Notice, or until April 1, 2024, to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). The Notice stated that if at any time during the compliance period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The Notice also stated that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. The Notice stated that if the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. The Notice also stated that if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance that any such appeal would be successful. There are no assurances that the Company will be able to regain compliance with the Rule or will otherwise be in compliance with other Nasdaq listing requirements. Tillkännagivande • Sep 02
Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023 Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023. Tillkännagivande • Aug 06
Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 4,800,000
Price\Range: $1.35
Discount Per Security: $0.0945
Security Name: Pre-Funded Units
Security Type: Equity/Derivative Unit
Securities Offered: 1,130,000
Price\Range: $1.3499
Discount Per Security: $0.09449 Tillkännagivande • May 26
Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC. Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK’s stockholders. The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) completed the acquisition of DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on May 25, 2023. In connection with the merger, Ebrahim Versi assumed the role of Chief executive officer and Chairman of the Board and David J. Marguglio previously Chief Executive Officer of Adamis, will assume the role of President and Chief Operating Officer of the combined company. Ebrahim Versi and DMK board member Jannine Versi, have been appointed to the Board and join the pre-merger Adamis directors Howard C. Birndorf, Meera J. Desai, PhD, and Vickie Reed as the new Board of the combined company. Adamis Chairman, Richard C. Williams, and David J. Marguglio resigned their prior director roles in connection with the closing of the merger. Combined company will have commercial products and a library of development candidates, including two clinical stage programs.DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder. Tillkännagivande • May 09
Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023 Adamis Pharmaceuticals Corporation announced that they will report Q1, 2023 results at 1:00 PM, Pacific Standard Time on May 15, 2023 Board Change • Mar 04
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 23
Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Third quarter 2021 results: US$0.035 loss per share (up from US$0.10 loss in 3Q 2020). Revenue: US$760.0k (down 82% from 3Q 2020). Net loss: US$5.17m (loss narrowed 31% from 3Q 2020). Revenue missed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 27% compared to a 19% growth forecast for the industry in the United Kingdom. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
